Risk factors for metabolic disorders in patients with polycystic ovary syndrome

Yesmine Elloumi; Abbes Wissal; Mouna Elleuch; kouloud boujelben; Hadjkacem Faten; Nadia Charfi; Mouna Mnif; mohamed abid; Salah Dhoha Ben; Majdoub Nabila Rekik

doi:10.1530/endoabs.110.EP988

EP988

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP988 | DOI: 10.1530/endoabs.110.EP988

ECEESPE2025 ePoster Presentations Metabolism, Nutrition and Obesity (164 abstracts)

Risk factors for metabolic disorders in patients with polycystic ovary syndrome

Yesmine Elloumi ¹ , Abbes Wissal ¹ , Mouna Elleuch ¹ , kouloud boujelben ¹ , Hadjkacem Faten ¹ , Nadia Charfi ¹ , Mouna Mnif ¹ , mohamed abid ¹ , Dhoha Ben Salah ¹ & Nabila Rekik Majdoub ¹

Author affiliations

¹Hedi Chaker University Hospital, Endocrinology Department, Sfax, Tunisia

JOINT995

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder often associated with various metabolic disturbances. The presence of metabolic disorders, such as diabetes, dyslipidemia, and hyperuricemia, may complicate the clinical management of PCOS patients. This study aims to compare the clinical and metabolic profiles of PCOS patients with and without these metabolic complications, providing insights into their potential impact on the disease.

Methods: A retrospective comparative study was conducted on 49 patients followed for PCOS in the Endocrinology Department at Hedi Chaker University Hospital, Sfax, Tunisia. The patients were classified into two groups: Group 1 included 13 patients with PCOS and metabolic disorders (diabetes, dyslipidemia, hyperuricemia), while Group 2 consisted of 36 patients without such disorders.

Results: The mean BMI was 29.4 in Group 1 (G1) vs 25.2 in Group 2 (G2); P = 0.001. Obesity or overweight was observed in 77% of G1 patients vs 47% of G2 patients; P = 0.06, with an android type distribution in 54% of cases. Acanthosis nigricans was found in 46% of G1 patients vs 3% of G2 patients; P = 0.001. Menstrual cycle disorders were reported by 77% of G1 patients and 83% of G2 patients; P = 0.9, including amenorrhea in 18 cases and oligomenorrhea in 22 cases. Infertility or subfertility was found in 22% of G1 patients vs 26% of G2 patients; P = 0.7. Hirsutism was present in 38% of G1 patients vs 47% of G2 patients; P = 0.5. Hormonal analysis revealed an average LH of 12 IU/ml and an average FSH of 7 IU/ml, with no significant differences between the two groups. The average estradiol level was 38 pg/ml, while the average testosterone level was 1.11 ng/ml. Hyperprolactinemia was detected in 14 patients (28%), with 12 cases in G1.

Conclusion: Aside from abnormalities related to insulin resistance, there were no statistically significant differences in the clinical and hormonal profile of this syndrome in the presence or absence of metabolic disorders.